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Background. Malaria retinopathy has been proposed as marker of “true” cerebral malaria (CM), ie, coma due to Plasmodium 
falciparum vs coma due to other causes, with incidental P falciparum parasitemia. Plasma P falciparum histidine-rich protein-2 
(PfHRP2) concentrations distinguish retinopathy-positive (RP) from retinopathy-negative (RN) CM but have not been compared 
between RN CM and other forms of severe malaria or asymptomatic parasitemia (AP).
Methods. We compared plasma PfHRP2 concentrations in 260 children with CM (247 examined for retinopathy), 228 children 
with severe malarial anemia (SMA), and 30 community children with AP.
Results. Plasmodium falciparum HRP2 concentrations were higher in children with RP CM than RN CM (P = .006), with an 
area under the receiver operating characteristic curve of 0.61 (95% confidence interval, 0.53–0.68). Plasmodium falciparum HRP2 
concentrations and sequestered parasite biomass were higher in RN CM than SMA (both P < .03) or AP (both P < .001).
Conclusions. Plasmodium falciparum HRP2 concentrations are higher in children with RN CM than in children with SMA or 
AP, suggesting that P falciparum is involved in disease pathogenesis in children with CM. Plasmodium falciparum HRP2 concen-
trations may provide a more feasible and consistent assessment of the contribution of P falciparum to severe disease than malaria 
retinopathy.
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In 2015, there were an estimated 438 000 deaths due to malaria, 
90% of which occurred in Africa, and 70% of all deaths occurred 
in children less than 5 years of age [1, 2]. Mortality due to severe 
malaria (SM), including cerebral malaria (CM) and SM anemia 
(SMA), is most often due to Plasmodium falciparum. Cerebral 
malaria is clinically defined as coma with asexual P falciparum 
parasitemia and no other known cause of coma. The hallmark 
in the brain pathology of children who die of CM is the seques-
tration of parasitized erythrocytes in the cerebral microvascula-
ture, but pathogenesis is also thought to involve inflammation, 
rosette formation, and dysregulated hemostasis [3, 4].
During the course of P falciparum blood-stage replication, 
the parasite produces P falciparum histidine-rich protein-2 
(PfHRP2) [5]. Most PfHRP2 produced is released into plasma, 
which allows for estimation of the amount of PfHRP2 produced 
per parasite per erythrocytic cycle [6]. Plasmodium falciparum 
HRP2 levels have been used to estimate the total parasite bio-
mass during an infection [7–9]. Studies investigating PfHRP2 
levels as a prognostic indicator in SM have shown that PfHRP2 
levels (1) can distinguish between uncomplicated malaria (UM) 
and SM [10–12] and (2) can predict which individuals with UM 
will go on to develop SM [10]. Plasmodium falciparum HRP2 
concentrations can also predict mortality in CM [8, 12, 13]. In 
addition, recent in vitro and experimental CM studies suggest 
that PfHRP2 may be directly involved in CM pathogenesis, 
through activation of the inflammasome and disruption of the 
blood-brain barrier [14, 15].
Accurate diagnosis of CM, ie, coma due to P falciparum, 
rather than coma due to other causes with incidental P falci-
parum parasitemia, remains a challenge in malaria-endemic 
areas. An autopsy study in Malawian children demonstrated 
(1) that 23% of children clinically defined as CM had other 
causes for their coma and death and lacked sequestration of 
parasitized erythrocytes in the brain microvasculature [16] and 
(2) that malaria retinopathy at hospitalization was a sensitive 
and specific indicator of brain parasite sequestration. Therefore, 
malaria retinopathy has been proposed as marker of “true” CM, 
as opposed to coma with incidental P falciparum parasitemia.
Total parasite biomass, calculated from plasma PfHRP2 lev-
els, successfully distinguished retinopathy-positive (RP) from 
retinopathy-negative (RN) CM in a different study in Malawian 
children [17]. However, there has been no assessment to date of 
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the relative concentrations of PfHRP2 or estimation of seques-
tered parasite biomass in CM RN children compared with chil-
dren with other forms of SM or children with asymptomatic 
parasitemia (AP). If children with RN CM have PfHRP2 levels 
greater than those with SMA, a known complication of P falci-
parum, this would suggest that P falciparum is involved in dis-
ease pathogenesis in RN CM and that RN CM is therefore also 
true CM. This is important for research studies and for clinical 
purposes, because 30%–40% of children with the World Health 
Organization diagnosis of CM are RN [17, 18]. Inclusion of only 
RP children in studies of CM, as in some recent studies [19, 20], 
might exclude substantial numbers of children with true CM, 
and lack of retinopathy on clinical exam could be misconstrued 
as evidence that P falciparum is not a cause of coma in the child.
In the present study, we used PfHRP2 testing to compare 
total, circulating, and sequestered parasite biomass in children 
with RP and RN CM with children with SMA and with commu-
nity children (CC) with AP who were from the same neighbor-
hoods or households as children with CM or SMA
METHODS
Study Population, Clinical Assessment, and Ethical Approval
The study was performed at Mulago National Referral and 
Teaching Hospital in Kampala as previously described [21]. In 
brief, children with CM, SMA, or CC between 18 months and 
12 years of age were enrolled. Cerebral malaria was defined as 
follows: (1) coma (Blantyre Coma Score ≤2 if <5 years or Glasgow 
coma score ≤8 if ≥5 years); (2) P falciparum on blood smear; and 
(3) no other known cause of coma (eg, meningitis, a prolonged 
postictal state, or hypoglycemia-associated coma reversed by glu-
cose infusion). Severe malaria anemia was defined as presence of 
P falciparum on blood smear in children with a hemoglobin level 
≤5 g/dL. Drs. Susan Lewallen and Simon Harding, ophthalmolo-
gists with extensive experience in evaluation of malaria retinop-
athy in Malawi, trained study medical officers and pediatricians 
in direct and indirect ophthalmoscopic examination for malaria 
retinopathy. Medical officers were assessed for accurate evalua-
tion of retinal findings by Drs. Harding in a limited number of 
children with CM (n  =  1 to 3), because children with CM are 
admitted only intermittently, and for proficiency in indirect oph-
thalmoscopy through a simulation exercise in which they were 
required to read letters of newspaper text behind a marble using 
the indirect ophthalmoscope. After training, medical officers 
accurately characterized presence of retinopathy in all children 
with CM examined, when compared to findings by Drs. Lewallen 
and Harding. Medical officers assessed children for malaria retin-
opathy, and lead pediatrician investigators provided evaluation of 
medical officer exams throughout the study.
Children with CM or SMA were managed according to the 
Ugandan Ministry of Health treatment guidelines current at 
the time of the study. These included (1) intravenous quinine 
treatment followed by oral quinine for SM while admitted and 
(2) artemisinin combination therapy for outpatient follow-up 
therapy. Healthy CC were recruited from the extended family 
or household compound area of children with CM or SMA. 
Peripheral blood smears were prepared for all CC, and CC with 
P falciparum infection were treated with artemether-lumefan-
trine. Microscopy for peripheral parasitemia and laboratory 
testing for complete blood and platelet counts, and glucose and 
human immunodeficiency virus testing were performed as pre-
viously described [21].
Written informed consent was obtained from parents or 
guardians of study participants. The studies were reviewed 
and approved by the Ugandan National Council for Science 
and Technology, the Makerere University School of Medicine 
Research and Ethics Committee, and the University of 
Minnesota Institutional Review Board.
Plasmodium falciparum Histidine-Rich Protein-2 Testing
Plasma PfHRP2 levels were quantified using the commercially 
available Malaria Ag CELISA kit (Cellabs, Brookvale, Australia). 
Plasma was diluted 1:2400. Samples with results above or below 
the range of the standard curve were retested at a dilution of 
1:24 000 or 1:200, respectively. To assess intra-assay reproduci-
bility, 10% of samples were randomly selected from each assay 
plate to retest on subsequent plates. The coefficient of variance 
for these samples was 22%. For analysis, PfHRP2 concentra-
tions below the lowest detectable standard were transformed to 
lowest detectable standard value (4.8 ng/mL).
Estimation of Parasite Biomass
Parasite biomass (total, circulating, sequestered) was estimated 
using previously published calculations [7, 8]. In brief, the cal-
culation for total and circulating biomass is Ptot = 7.3 × PfHRP2 
[g/L] × (1-hematocrit) × body weight [kg] × 1013; Pcirc = par-
asites/μL × 106 × hematocrit × blood volume [estimated at 
0.08 L/kg × body weight]. Sequestered biomass is calculated as 
Pseq = Ptot − Pcirc.
Statistical Analyses
All statistical analyses were completed using STATA SE version 
12.0 (Stata Corporation, College Station, TX). Study participant 
characteristics and PfHRP2 concentrations were compared 
using the Wilcoxon rank-sum, Spearman’s rank correlation, 
and Pearson’s χ2 tests. Differences were considered significant at 
P < .05. Receiver operating characteristic (ROC) analyses were 
used to determine whether PfHRP2 could distinguish between 
disease groups.
RESULTS
Clinical and Laboratory Characteristics of Study Children
A total of 267 children with CM, 232 children with SMA, and 
214 CC were enrolled in the study, and 30 of the CC had AP. 
Two hundred sixty children with CM, 228 with SMA, and all 30 
AP had sufficient plasma for PfHRP2 testing. A higher propor-
tion of children with SM compared with AP were male, and, as 
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expected, children with SM had lower hemoglobin levels and 
lower platelet counts than AP (Table 1).
Malaria Retinopathy in Children With Cerebral Malaria 
Two hundred forty-seven children with CM had a retinal 
examination, and 161 of these children (65.2%) had 1 or 
more features of malarial retinopathy (retinal hemorrhages, 
macular whitening, peripheral whitening, or vessel changes). 
Some of the children did not have fundoscopy due to death 
before examination, inadequate pupil dilation, or awaking 
from coma before the exam could be performed. Among the 
161 children with CM who had retinopathy, the most com-
mon findings were retinal hemorrhages (n  =  136, 84.5%), 
macular whitening (n  =  83, 51.6%), peripheral whitening 
(n = 57, 35.4%), and vessel changes (n = 57, 35.4%). Among 
children with CM, RP children had significantly lower hemo-
globin levels and lower platelet counts than RN children, but 
no other demographic or clinical characteristics differed by 
retinopathy findings (Table 2). Demographic and clinical dif-
ferences seen between children with SMA and CM were seen 
regardless of whether the children with CM were RP or RN 
(Table 2).
Plasmodium falciparum Histidine-Rich Protein-2 Levels in Children With 
Severe Malarial Anemia and in Children With Cerebral Malaria With and 
Without Retinopathy
Plasmodium falciparum HRP2 levels were highest in chil-
dren with CM but higher in children with SMA than in AP 
(Figure 1A). Among children with CM, RP children had signif-
icantly higher levels of PfHRP2 than RN children and children 
with SMA (Figure  1B). In addition, PfHRP2 levels were sig-
nificantly higher in RN CM children than children with SMA 
(Figure 1B and Table 4). Among the 30 CC with AP, PfHRP2 
levels were significantly lower (median, 4.8 ng/mL; interquartile 
range [IQR], 4.8–106) than in children with RP CM (median, 
3163  ng/mL; IQR, 1538–5405; P  <  .001), RN CM (median, 
2365  ng/mL; IQR, 516–5176; P  <  .001) or SMA (median, 
929 ng/mL; IQR, 379–2735; P < .001).
Utility of Plasmodium falciparum Histidine-Rich Protein-2 Levels to 
Distinguish Between Retinopathy-Positive and Retinopathy-Negative 
Cerebral Malaria and Asymptomatic Parasitemia 
Receiver operating characteristic analyses revealed that the area 
under the ROC curve (AUROC) of PfHRP2 for RP vs RN CM 
was 0.61 (95% confidence interval [CI], 0.53–0.68) (Figure 2). 
A cutoff of 1392 ng/mL maximized sensitivity and specificity 
for RP CM compared with RN CM (sensitivity 78.3% [95% CI, 
71.1%–84.4%], specificity 41.9% [95% CI, 31.3%–60.0%], nega-
tive predictive value (NPV) 50.7% [95% CI, 38.6%–62.8%], and 
positive predictive value (PPV) 71.6% [95% CI, 64.3%–78.1%]). 
Using the PfHRP2 cutoff value of 1700  ng/mL from Seydel 
et al [17] yielded sensitivity for RP vs RN CM of 72.7% (95% 
CI, 65.1%–79.4%), specificity 44.2% (95% CI, 33.5%–55.3%), 
NPV 46.3% (95% CI, 35.3%–57.7%), and PPV 70.9% (95% CI, 
63.3%–77.7%).
Plasmodium falciparum HRP2 concentration distinguished 
well between CM and AP (AUROC 0.97; 95% CI, 0.94–1.0), 
including between RP CM and AP (AUROC 0.98; 95% CI, 
0.96–1.0) and between RN CM and AP (AUROC 0.95; 95% CI, 
0.91–0.99). A  PfHRP2 cutoff value of 232  ng/mL provided a 
sensitivity of >90% for RP and RN CM compared with AP, with 
optimal specificity: RP CM, sensitivity 96.9% (95% CI, 92.9%–
99.0%), specificity 90.0% (95% CI, 73.5%–97.9%), NPV 84.4% 
(95% CI, 67.2%–94.7%), PPV 98.1% (95% CI, 94.6%–99.6%); 
RN CM, sensitivity 91.9% (95% CI, 84.0%–96.7%), specificity 
90.0 % (95% CI, 73.5% – 97.9%), NPV 79.4% (95% CI, 62.1%–
91.3%), and PPV 96.3% (95% CI, 89.7%–99.2%).
Plasmodium falciparum Histidine-Rich Protein-2 Levels and Mortality
Among children with CM, PfHRP2 levels were significantly 
higher in children who died than in survivors (survived [n = 229; 
median, 2654; IQR, 996–5362] vs died [n = 31; median, 4514; 
IQR, 2489–7469], P = .013) (Figure 3A). A nonsignificant trend 
toward increased mortality was seen in RP (23 of 161, 14.3%) vs 
RN (6 of 86, 7.0%) children. The PfHRP2 levels in RP and RN 
children with fatal CM did not differ (P = .81); however, among 
Table 1. Clinical and Laboratory Characteristics of Children With Cerebral Malaria, Severe Malarial Anemia, and Community Children With Asymptomatic 
Parasitemia
Characteristic CMa N SMAa N APa N P, CM SMAb P, CM APb P, SMA APb
Sex, n (%) female 106 (40.8) 260 89 (39.0) 228 106 (53.3) 30 .70 .54 .42
Age, years 3.99 (2.0) 260 3.37 (1.7) 228 3.96 (1.5) 30 <.001 .95 .072
Weight, kg 14.4 (4.4) 260 12.8 (3.7) 228 15.0 (3.9) 30 <.001 .52 .003
Hemoglobin, g/dL 7.0 (2.3) 260 3.8 (0.9) 228 11.3 (1.8) 27 <.001 <.001 <.001
Platelets, 106/mL 83 (82) 255 184 (138) 226 250 (127) 27 <.001 <.001 .019
Parasite density, parasites/μL,  
median (interquartile range)
48 080  
(11 120–282 400)
260 36 150  
(10 510–144 670)
228 1290  
(580–8360)
30 .03 <.001 <.001
HIV positive, n (%) 5 (2.1) 241 6 (2.7) 225 0 (0) 30 .67 .43 .37
Mortality, n (%) 31 (11.9) 260 1 (0.4) 228 0 (0) 30 <.001 .05 .72
Values in bold indicate P <.05.
Abbreviations: AP, asymptomatic parasitemia; CM, cerebral malaria; HIV, human immunodeficiency virus; SMA, severe malarial anemia.
aData are mean (standard deviation) unless otherwise indicated.
bCompared by χ2 test (sex, HIV status, and mortality), Student’s t test (age, weight, hemoglobin, platelet count), or Wilcoxon rank-sum test (parasite density).
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survivors of CM, PfHRP2 levels were higher in RP children 
than RN children (P = .007) (Figure 3B).
Parasite Biomass
Total, circulating, and sequestered parasite biomass all differed 
significantly between CM, SMA, and CC groups, with levels high-
est in CM, followed by SMA, followed by CC (Table 3). Total and 
sequestered, but not circulating, parasite biomass were higher in 
RP than RN CM, and total, sequestered, and circulating parasite 
biomass were all higher in RP or RN CM than in SMA (Table 4). 
Finally, total, sequestered, and circulating parasite biomass were 
higher in RN CM than in AP (P < .001 for all) (Tables 3 and 4).
DISCUSSION
In the present study, although plasma PfHRP2 concentrations 
distinguished between RP and RN CM, plasma PfHRP2 con-
centrations and total and sequestered parasite biomass in chil-
dren with RN CM were significantly higher than in children 
with SMA, another form of SM, and far higher than in children 
with asymptomatic P falciparum parasitemia. Because PfHRP2 
concentrations and sequestered parasite biomass are markers of 
disease severity in malaria, the study findings support a role for 
P falciparum in the pathogenesis of RN CM.
An important limitation of the present study and any study 
of malaria retinopathy is the expertise of those doing the testing. 
The level of expertise required for indirect and direct ophthalmo-
scopy is available in few African or Asian medical centers. In the 
present study, medical officers trained by expert ophthalmologists 
with expertise in assessment of malaria retinopathy did all primary 
assessments of malaria retinopathy. The significant difference in 
PfHRP2 levels between RP and RN children with CM, together 
with the similar percentage of RP children among all children with 
CM in the present study and in a Malawian study on PfHRP2 levels 
in RP and RN CM [17] (66.7% and 70.3%, respectively) suggest a 
reliable assessment of retinopathy in our study.
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Figure 1. Plasmodium falciparum histidine-rich protein-2 (PfHRP2) levels in children with severe malaria. Black horizontal bars within the scatter plots indicate the group 
median, and black horizontal bars above the scatter plots show the group comparisons and associated P values. (A) Plasma HRP2 levels in children with cerebral malaria 
(CM), children with severe malarial anemia (SMA), and community children with asymptomatic parasitemia (AP). (B) Plasma HRP2 levels in children with SMA or with CM 
and retinopathy (RP) or no retinopathy (RN).
Table 2. Clinical and Laboratory Characteristics of Children With Retinopathy-Positive Cerebral Malaria, Retinopathy-Negative Cerebral Malaria, and 
Severe Malarial Anemia
Characteristic RPa N RNa N SMAa N P, RP RNb P, RP SMAb P, RN SMAb
Sex, n (%) female 69 (42.9) 161 34 (39.5) 86 89 (39.0) 228 .61 .45 .94
Age, years 3.84 (2.0) 161 4.12 (1.9) 86 3.37 (1.7) 228 .28 .01 <.001
Weight, kg 14.1 (4.5) 161 14.8 (4.4) 86 12.8 (3.7) 228 .23 .003 <.001
Hemoglobin, g/dL 6.5 (2.2) 161 7.7 (2.2) 86 3.8 (0.9) 228 <.001 <.001 <.001
Platelets, 106/mL 74 (52) 157 95 (107) 86 184 (138) 226 0.04 <.001 <.001
Parasite density, parasites/μL, 
median (interquartile range)
47 880  
(9920–294 500)
161 49 765  
(15 480–273 100)
86 36 150  
(10 510–144 670)
228 .46 .10 .03
HIV positive, n (%) 2 (1.3) 149 3 (3.7) 81 6 (2.7) 225 .24 .39 .64
Mortality, n (%) 23 (14.3) 161 6 (7.0) 86 1 (0.4) .09 <.001 <.001
Values in bold indicate P <.05.
Abbreviations: HIV, human immunodeficiency virus; RN, retinopathy negative; RP, retinopathy positive; SMA, severe malarial anemia.
aData are mean (standard deviation) unless otherwise indicated.
bCompared by χ2 test (sex, HIV status, and mortality), Student’s t test (age, weight, hemoglobin, platelets), or Wilcoxon rank-sum test (parasite density).
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In the Malawi study, PfHRP2 levels distinguished bet-
ter between RP and RN CM than in the present study 
(AUROC = 0.90 vs 0.63, respectively). In addition, in the pres-
ent study, PfHRP2 levels did not differ between RP and RN 
children who died, whereas they did differ in children who sur-
vived. In the Malawi studies, exams were done by ophthalmol-
ogists as opposed to medical officers, and therefore they were 
likely to have greater sensitivity and specificity for detection 
of malaria retinopathy. However, because our medical officers 
were trained by the expert ophthalmologists who conducted the 
Malawi studies, we believe that our study assessment of malaria 
retinopathy is an optimal “real-world” assessment and valid for 
testing the question of whether RN CM, as assessed in the field, 
reflects coma due to causes other than P falciparum. In addi-
tion, PfHRP2 levels distinguished well between RN CM and AP 
in this community, suggesting that children with RN CM are 
unlikely to have incidental parasitemia. The overlap of PfHRP2 
levels in children with RN CM and children with SMA further 
argues that P falciparum is involved in this disease process as 
it is in SMA. Given the lower mortality in the RN than RP CM 
group (14.3% vs 7.0%), it is possible that RN CM represented a 
less severe form of CM, consistent with the lower sequestered 
parasite biomass seen in RN CM. This could have led to a lack 
of malaria retinopathy or less easily detectable malaria retin-
opathy. It is also possible that children with RN CM do have P 
falciparum as the cause of coma but are diagnosed earlier and so 
have not yet had time to develop retinopathy.
A study in Gambian children showed that, as in this study, 
children with SMA have a high sequestered parasite biomass 
[9], whereas a study in Malawi showed that 53% of children 
with SMA had malaria retinopathy [22], demonstrating that 
retinopathy (and presumably associated brain-level seques-
tration) are not exclusive to CM and therefore not a sufficient 
factor for development of CM. Taken together, the findings of 
the present study and previous studies suggest that sequestra-
tion in the postcapillary venules of the brain is an important 
component of the disease process in most cases of CM but that 
sequestration in the brain, as reflected by malaria retinopathy, 
does not inevitably lead to coma. The study findings do not nec-
essarily contradict the findings of the landmark study by Taylor 
et al [16], showing that parasites were not present in children 
with RN CM on autopsy, because that study assessed only chil-
dren who died of CM. It is possible that survivors of CM differ 
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Figure  2. Receiver operating characteristic (ROC) analyses of Plasmodium fal-
ciparum histidine-rich protein-2 (PfHRP2) concentrations in children with cerebral 
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from those who die of CM, and that those who die have more 
advanced disease in which retinopathy is almost uniformly 
present, whereas some who survive may do so without develop-
ment of clinically discernible retinopathy.
Assessment of PfHRP2 levels can be affected by several fac-
tors, including variations in parasite genotype or gene expres-
sion [23–26], prior malaria exposure [27], type of detection 
assay used, and stage of parasite at time of assessment. None 
of these are likely to have had a major effect on the major study 
finding of high PfHRP2 levels in RN CM, because the kit for 
antibody testing was used in the prior large studies of PfHRP2 
levels in SM [7–9, 17], and all of these factors would gener-
ally lead to lack of detection of PfHRP2, whereas our findings 
demonstrated high levels of PfHRP2 in children with RN CM. 
Optimal cutoffs for prediction of severe disease, mortality, and 
malaria-attributable disease will require additional studies. The 
coefficient of variance for PfHRP2 testing in the present study 
was 22%, which could have contributed to a degree of variability 
in results.
Plasmodium falciparum HRP2 may also play a role in disease 
pathogenesis. Pathways through which PfHRP2 could lead to 
severe disease in malaria include mediation of the formation 
of hemozoin, detoxifying heme for the parasite, and binding of 
heparin and other glycosaminoglycans [28], leading to micro-
vascular sequestration. Plasmodium falciparum HRP2 may also 
have an immunomodulatory role in SM, because exposure of T 
cells to PfHRP2 can inhibit the expression of CD69, decrease 
interferon-γ secretion, and decrease lymphocyte proliferation, 
potentially dampening initial protective immune responses 
against the parasite [29]. Recently, Pal et al [15] demonstrated 
(1) that disruption of the human microvascular endothelial bar-
rier depends on expression of PfHRP2 and (2) that recombinant 
or purified HRP2 recapitulated these effects through activation 
of the inflammasome, which decreased integrity of tight junc-
tions and increased endothelial permeability. They subsequently 
showed (1) that intravenous administration of PfHRP2 induced 
blood-brain barrier leakage in uninfected mice and (2) that 
PfHRP2 infusion in Plasmodium berghei-infected mice increased 
early mortality from experimental CM [14]. These findings pro-
vide the clearest evidence to date that PfHRP2 may be involved 
in disease pathogenesis in CM. The increasing PfHRP2 concen-
trations seen with increasing disease severity (SMA, RN CM, RP 
CM) in this study are consistent with this idea.
CONCLUSIONS
In summary, the present study shows that children with RN CM 
have substantial sequestered P falciparum biomass, which sug-
gests that P falciparum is a contributor to disease pathogenesis 
in children with RN CM, as it is in RP CM. It is possible that 
some children with RN CM in this study were misclassified and 
malaria retinopathy, but the findings likely reflect a close to opti-
mal capture of malaria retinopathy within most clinical settings 
in sub-Saharan Africa. The study data add to the complexity 
of defining true CM but support the idea that measurement of 
PfHRP2 levels, for which low-cost, low-training, point-of-care 
devices should be feasible, are useful in distinguishing whether 
severe disease is due to P falciparum malaria or other causes. We 
are pursuing investigations of factors involved in endothelial 
activation, inflammation, and hemostasis in children with RN 
and RP CM, to better determine whether the pathophysiology 
Table 3. Parasite Biomass ×1010
Parasite Biomass CM (N = 260)a SMA (N = 228)a AP (N = 30)a P, CM SMAb P, CM APb P, SMA APb
PfHRP2, ng/mL 2864 (1092–5537) 929 (379–2735) 4.8 (4.8–105.6) <.001 <.001 <.001
Total 223 (87.8–450) 78.5 (29.2–191) 0.4 (0.3–9.5) <.001 <.001 <.001
Circulating 5.2 (1.2–28.6) 3.7 (1.0–13.2) 0.1 (0.1–1.0) .006 <.001 <.001
Sequestered 188 (70.4–414) 64.7 (21.4–178) 0.3 (0.1–7.4) <.001 <.001 <.001
Values in bold indicate P <.05.
Abbreviations: AP, asymptomatic parasitemia in community children; CM, cerebral malaria; PfHRP2, Plasmodium falciparum histidine-rich protein-2; SMA, severe malarial anemia.
aData are median (interquartile range). N = 27 for AP total and sequestered biomass.
bCompared by Wilcoxon rank-sum test.
Table 4. Parasite Biomass ×1010 in Children With Severe Malaria
Parasite Biomass RP (N = 161)a RN (N = 86)a SMA (N = 228)a P, RP RNb P, RP SMAb P, RN SMAb
PfHRP2, ng/mL 3163 (1538–5405) 2365 (516–5176) 929 (379–2735) .006 <.001 .003
Total 266 (123–448) 176 (37.7–357) 78.5 (29.2–191) .007 <.001 .002
Circulating 4.9 (1.1–32.4) 5.7 (1.7–23.6) 3.7 (1.0–13.2) .36 .04 .007
Sequestered 237 (103–416) 128 (25.4–351) 64.7 (21.4–178) .005 <.001 .02
Values in bold indicate P <.05.
Abbreviations: PfHRP2, Plasmodium falciparum histidine-rich protein-2; RN, retinopathy negative cerebral malaria; RP, retinopathy positive cerebral malaria; SMA, severe malarial anemia.
aData are median (interquartile range).
bCompared by Wilcoxon rank-sum test.
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of RN CM is distinguishable from RP CM. Additional studies, 
ideally with photographic evidence of retinopathy, are needed 
to determine whether the present study findings are more 
broadly applicable to other malaria-endemic areas.
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